Literature DB >> 9531271

Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery.

J K Sandberg1, P Grufman, E Z Wolpert, L Franksson, B J Chambers, K Kärre.   

Abstract

To examine possible interference patterns between immunodominant CTL Ags, we analyzed the response to mixtures of five well-characterized H-2Kb-restricted epitopes, each of which had earlier been described as immunodominant within its antigenic system. Clear patterns of dominance were observed between peptides in the mixture, with the CTL response focusing on the Sendai virus nucleoprotein 324-332 and vesicular stomatitis virus nucleoprotein 52-59 epitopes. The dominance of these epitopes correlated with high CTL availability. Subdominance of the OVA(257-264) and the MCF1233 murine leukemia virus envelope 574-581 peptides could not be explained by inferior ability to bind and stabilize MHC class I molecules. Interestingly, immunodominance was broken if the peptide mixture was pulsed on bone marrow-derived dendritic cells, a mode of immunization allowing efficient recognition of a broader set of specificities. Our results show that immunodominance is neither an absolute feature of a given epitope nor does it apply only in relation to other epitopes within the same protein, micro-organism, or cell. Novel "superdominant" hierarchies emerge in the response against multiple "dominant" epitopes. A T cell competition model to explain the data in terms of a balance influenced by CTL frequencies and available APC capacity is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531271

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  HIV vaccine development at Duke University Medical Center.

Authors:  B F Haynes; H X Liao; H F Staats; M S Alam; K J Weinhold; D C Montefiori
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance.

Authors:  Ian A York; Michael A Brehm; Sophia Zendzian; Charles F Towne; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

3.  Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.

Authors:  Jay Friedman; Ellen C Moore; Paul Zolkind; Yvette Robbins; Paul E Clavijo; Lilian Sun; Sarah Greene; Megan V Morisada; Wojciech K Mydlarz; Nicole Schmitt; James W Hodge; Hans Schreiber; Carter Van Waes; Ravindra Uppaluri; Clint Allen
Journal:  Clin Cancer Res       Date:  2019-10-23       Impact factor: 12.531

Review 4.  How patients with an intact immune system develop head and neck cancer.

Authors:  Sarah Greene; Priya Patel; Clint T Allen
Journal:  Oral Oncol       Date:  2019-03-18       Impact factor: 5.337

5.  Mice deficient in perforin, CD4+ T cells, or CD28-mediated signaling maintain the typical immunodominance hierarchies of CD8+ T-cell responses to influenza virus.

Authors:  Weisan Chen; Jack R Bennink; Phillip A Morton; Jonathan W Yewdell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  CD8+ T-cell cross-competition is governed by peptide-MHC class I stability.

Authors:  Ian Galea; Jana Stasakova; Melanie S Dunscombe; Christian H Ottensmeier; Tim Elliott; Stephen M Thirdborough
Journal:  Eur J Immunol       Date:  2011-11-28       Impact factor: 5.532

7.  No evidence for competition between cytotoxic T-lymphocyte responses in HIV-1 infection.

Authors:  Helen R Fryer; Almut Scherer; Annette Oxenius; Rodney Phillips; Angela R McLean
Journal:  Proc Biol Sci       Date:  2009-09-23       Impact factor: 5.349

8.  CD8 T cell epitope distribution in viruses reveals patterns of protein biosynthesis.

Authors:  Carmen M Diez-Rivero; Pedro A Reche
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

Review 9.  Whole Tumor Antigen Vaccines: Where Are We?

Authors:  Cheryl Lai-Lai Chiang; George Coukos; Lana E Kandalaft
Journal:  Vaccines (Basel)       Date:  2015-04-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.